Clinical activity of immunotherapy-based combination first-line therapies for metastatic renal cell carcinoma: the right treatment for the right patient.
Cancer du rein
First line
Immunotherapy
Immunothérapie
Kidney cancer
Metastatic
Métastatique
Première ligne
Targeted therapy
Thérapie ciblée
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
30
6
2022
Statut:
ppublish
Résumé
Immunotherapy (IO) with checkpoint inhibitors with or without anti-angiogenic tyrosine kinase inhibitor (TKI)-based combinations have demonstrated superior efficacy over sunitinib for treatment-naive patients with metastatic clear-cell renal cell carcinoma (mRCC). Four of these combinations (nivolumab plus ipilimumab, pembrolizumab plus axitinib, nivolumab plus cabozantinib and pembrolizumab plus lenvatinib) represent new front-line standard-of-care options for mRCC patients, according to the International Metastatic RCC Database Consortium (IMDC) subgroups. Questions over the optimal treatment between IO-IO or IO-TKI combinations for mRCC patients in intermediate/poor IMDC risk groups and the optimal IO-TKI regimen for all IMDC risk groups remain unanswered. This review will focus on the biological pathways that have driven the hypothesis of a synergistic combination of such agents and their efficacy results, with consideration of response and survival outcomes in the overall population of phase three pivotal trials as well as in specific subgroups of interest.
Identifiants
pubmed: 35760470
pii: S0007-4551(22)00234-X
doi: 10.1016/S0007-4551(22)00234-X
pii:
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Immunologic Factors
0
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2S4-2S18Informations de copyright
Copyright © 2022 Elsevier Masson SAS. Tous droits réservés.